Investment Firms Begin Coverage of Complete Genomics

R.W. Baird, the Cowen Group, Jefferies, and UBS each recommended Complete Genomics' stock with target share prices significantly above the company's current trading price.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.